JPWO2021183529A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183529A5 JPWO2021183529A5 JP2022554294A JP2022554294A JPWO2021183529A5 JP WO2021183529 A5 JPWO2021183529 A5 JP WO2021183529A5 JP 2022554294 A JP2022554294 A JP 2022554294A JP 2022554294 A JP2022554294 A JP 2022554294A JP WO2021183529 A5 JPWO2021183529 A5 JP WO2021183529A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- administered
- cancer
- trastuzumab
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988312P | 2020-03-11 | 2020-03-11 | |
| US62/988,312 | 2020-03-11 | ||
| PCT/US2021/021527 WO2021183529A1 (en) | 2020-03-11 | 2021-03-09 | Methods of treating her2 mutant cancers with tucatinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517078A JP2023517078A (ja) | 2023-04-21 |
| JPWO2021183529A5 true JPWO2021183529A5 (https=) | 2024-03-19 |
| JP2023517078A5 JP2023517078A5 (https=) | 2024-03-19 |
Family
ID=75278374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554294A Pending JP2023517078A (ja) | 2020-03-11 | 2021-03-09 | ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230136203A1 (https=) |
| EP (1) | EP4118237A1 (https=) |
| JP (1) | JP2023517078A (https=) |
| KR (1) | KR20220152287A (https=) |
| CN (1) | CN115698338A (https=) |
| CA (1) | CA3174986A1 (https=) |
| IL (1) | IL296227A (https=) |
| MX (1) | MX2022011160A (https=) |
| WO (1) | WO2021183529A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060407A1 (en) | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| MX2022004699A (es) * | 2019-10-21 | 2022-08-08 | Seagen Inc | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| US20210239702A1 (en) * | 2018-06-14 | 2021-08-05 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
-
2021
- 2021-03-09 JP JP2022554294A patent/JP2023517078A/ja active Pending
- 2021-03-09 KR KR1020227034924A patent/KR20220152287A/ko not_active Withdrawn
- 2021-03-09 CA CA3174986A patent/CA3174986A1/en active Pending
- 2021-03-09 MX MX2022011160A patent/MX2022011160A/es unknown
- 2021-03-09 CN CN202180032665.9A patent/CN115698338A/zh active Pending
- 2021-03-09 US US17/910,265 patent/US20230136203A1/en active Pending
- 2021-03-09 EP EP21715395.6A patent/EP4118237A1/en active Pending
- 2021-03-09 WO PCT/US2021/021527 patent/WO2021183529A1/en not_active Ceased
- 2021-03-09 IL IL296227A patent/IL296227A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7219791B2 (ja) | Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法 | |
| AU2005314461B2 (en) | Methods and compositions for treating ocular disorders | |
| TWI398261B (zh) | 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 | |
| JP2023504786A (ja) | 抗がん効果増進のためのＥＲＲγ抑制剤を有効成分として含む組成物の用途 | |
| JP6382192B2 (ja) | 疾患および障害を検出、治療、および予防するための組成物および方法 | |
| KR20170031245A (ko) | 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물 | |
| US20230372342A1 (en) | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody | |
| JP2009512439A (ja) | 黒色腫におけるｃ−ＫＩＴ発癌遺伝子の変異 | |
| KR20230088634A (ko) | 간암 특이적 바이오 마커 및 이의 용도 | |
| US20230136203A1 (en) | Methods of treating her2 mutant cancers with tucatinib | |
| JPWO2021183529A5 (https=) | ||
| EP3303391A1 (en) | Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas | |
| JP2009511057A (ja) | 黄斑変性に関与する遺伝子 | |
| WO2023192944A1 (en) | Combination immune checkpoint inhibitor therapies | |
| US9351981B2 (en) | Use of PKC-iota inhibitors for the treatment of breast cancer | |
| US9709552B2 (en) | Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma | |
| KR20220152569A (ko) | 프리칼리크레인-연합된 병태를 치료하고 예방하는 조성물 및 방법 | |
| JP2020114857A (ja) | Ｒａｆ阻害剤及びタキサンの組み合わせ | |
| US7339039B2 (en) | Nucleic acids encoding receptor recognition factors, and methods of use thereof | |
| JP2003265184A (ja) | 被検者におけるグルココルチコイド製剤の有効性の検査方法 | |
| Peebles | hnRNP A2/B1 expression in neoplastic mouse lung cells | |
| WO2006037611A2 (en) | Methods for the early diagnosis of viral infections, inflammatory diseases, a predisposition for proliferative disorders or hyperplasia by analysing eag or erg expression levels | |
| EP1661990A1 (en) | Polypeptide specific to liver cancer, polynucleotide encoding the polypeptide and rna molecule inhibiting the expression of the polypeptide | |
| HK1113690B (en) | Methods and compositions for diagnosing age-related macular degeneration | |
| JP2005295917A (ja) | 生活習慣病の疾患マーカー及びその利用 |